• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.β-内酰胺/β-内酰胺酶抑制剂和厄他培南在拟杆菌菌血症中耐药的危险因素。
Antimicrob Agents Chemother. 2015 Aug;59(8):5049-51. doi: 10.1128/AAC.00046-15. Epub 2015 Jun 1.
2
Resistance to beta-lactam antibiotics in Bacteroides spp.拟杆菌属中对β-内酰胺类抗生素的耐药性
J Med Microbiol. 1997 Dec;46(12):979-86. doi: 10.1099/00222615-46-12-979.
3
Resistance to beta-lactam antibiotics in Bacteroides species.拟杆菌属中对β-内酰胺类抗生素的耐药性。
J Antimicrob Chemother. 1981 Dec;8 Suppl D:33-42. doi: 10.1093/jac/8.suppl_d.33.
4
Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study.新型β-内酰胺-β-内酰胺酶抑制剂单药与联合治疗耐药铜绿假单胞菌感染：一项多中心队列研究。
J Infect Chemother. 2024 Oct;30(10):1008-1014. doi: 10.1016/j.jiac.2024.03.015. Epub 2024 Mar 25.
5
Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.拟杆菌属菌血症的抗菌药物耐药性与临床结局：一项多中心前瞻性观察性试验的结果
Clin Infect Dis. 2000 Jun;30(6):870-6. doi: 10.1086/313805. Epub 2000 Jun 13.
6
beta-lactamases in bacteroides.拟杆菌中的β-内酰胺酶
Scand J Infect Dis Suppl. 1978(13):27-32.
7
A new potent beta-lactamase inhibitor, BRL 42715, with inherent activity against Bacteroides fragilis group strains.
Clin Infect Dis. 1993 Jun;16 Suppl 4:S335-8. doi: 10.1093/clinids/16.supplement_4.s335.
8
Risk factors and treatment outcome of ertapenem non-susceptible enterobacteriaceae bacteraemia.厄他培南不敏感肠杆菌科菌血症的危险因素及治疗结果
J Infect. 2013 Mar;66(3):294-6. doi: 10.1016/j.jinf.2012.11.010. Epub 2012 Nov 28.
9
Resistance of Bacteroides isolates recovered among clinical samples from a major Costa Rican hospital between 2000 and 2008 to ß-lactams, clindamycin, metronidazole, and chloramphenicol.2000年至2008年间，从哥斯达黎加一家主要医院的临床样本中分离出的拟杆菌对β-内酰胺类、克林霉素、甲硝唑和氯霉素的耐药性。
Rev Esp Quimioter. 2012 Dec;25(4):261-5.
10
Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study.台湾北部某大学医院产厄他培南耐药肺炎克雷伯菌菌血症的结局和特征：一项匹配病例对照研究。
J Microbiol Immunol Infect. 2012 Apr;45(2):113-9. doi: 10.1016/j.jmii.2011.09.026. Epub 2011 Dec 11.

引用本文的文献

1
Antimicrobial susceptibility against metronidazole and carbapenem in clinical anaerobic isolates from Pakistan.巴基斯坦临床厌氧分离株对甲硝唑和碳青霉烯类药物的药敏性。
Antimicrob Resist Infect Control. 2019 Jun 14;8:99. doi: 10.1186/s13756-019-0549-8. eCollection 2019.
2
Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.为儿科患者开具头孢洛扎/他唑巴坦：现状与未来影响
Paediatr Drugs. 2016 Feb;18(1):1-11. doi: 10.1007/s40272-015-0157-x.

本文引用的文献

1
Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.2010-2011 年加拿大脆弱拟杆菌群临床分离株的抗菌药物耐药性流行情况：CANWARD 监测研究。
Antimicrob Agents Chemother. 2012 Mar;56(3):1247-52. doi: 10.1128/AAC.05823-11. Epub 2011 Dec 27.
2
Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.2006-2009 年脆弱拟杆菌群及相关物种对碳青霉烯类药物耐药性的研究进展
Anaerobe. 2011 Aug;17(4):147-51. doi: 10.1016/j.anaerobe.2011.05.014. Epub 2011 Jun 2.
3
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.引起医院感染的临床重要厌氧菌和脆弱拟杆菌分离株的抗菌药物耐药性呈上升趋势：对碳青霉烯类药物出现耐药性。
Antimicrob Agents Chemother. 2008 Sep;52(9):3161-8. doi: 10.1128/AAC.00355-08. Epub 2008 Jul 14.
4
Reemergence of anaerobic bacteremia.厌氧菌血症的再度出现。
Clin Infect Dis. 2007 Apr 1;44(7):895-900. doi: 10.1086/512197. Epub 2007 Feb 14.
5
Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.厌氧细菌中抗生素耐药性的流行情况：令人担忧的发展态势。
Clin Infect Dis. 2004 Jul 1;39(1):92-7. doi: 10.1086/421558. Epub 2004 Jun 3.
6
Risk factors for mortality in patients with anaerobic bacteremia.厌氧菌血症患者死亡的危险因素。
Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):310-6. doi: 10.1007/s10096-004-1111-y. Epub 2004 Mar 13.
7
National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.脆弱拟杆菌群药敏性全国调查：1997 - 2000年趋势报告与分析
Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S126-34. doi: 10.1086/341934.
8
Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients.梭状芽胞杆菌血症：强调肝硬化患者的不良预后
J Microbiol Immunol Infect. 2001 Jun;34(2):113-8.
9
Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.拟杆菌属菌血症的抗菌药物耐药性与临床结局：一项多中心前瞻性观察性试验的结果
Clin Infect Dis. 2000 Jun;30(6):870-6. doi: 10.1086/313805. Epub 2000 Jun 13.
10
Clinical significance and outcome of anaerobic bacteremia.厌氧菌血症的临床意义及转归
Clin Infect Dis. 1998 Jun;26(6):1413-7. doi: 10.1086/516355.

β-内酰胺/β-内酰胺酶抑制剂和厄他培南在拟杆菌菌血症中耐药的危险因素。

Risk Factors for Resistance to β-Lactam/β-Lactamase Inhibitors and Ertapenem in Bacteroides Bacteremia.

机构信息

Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA

Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA.

出版信息

Antimicrob Agents Chemother. 2015 Aug;59(8):5049-51. doi: 10.1128/AAC.00046-15. Epub 2015 Jun 1.

DOI:10.1128/AAC.00046-15
PMID:26033720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4505236/
Abstract

The objective of this study was to determine risk factors for the development of resistance to β-lactams/β-lactamase inhibitors (βL/βLIs) and ertapenem among Bacteroides species bacteremia. We conducted a retrospective case-control study of 101 adult patients with Bacteroides species bacteremia at a 1,051-bed tertiary care medical center. The duration of exposure to βL/βLIs (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.08 to 2.31) was the only independent risk factor for resistance.

摘要

本研究旨在确定脆弱拟杆菌属菌血症患者对β-内酰胺类/β-内酰胺酶抑制剂（βL/βLIs）和厄他培南产生耐药的风险因素。我们对一家拥有 1051 张床位的三级保健医疗中心的 101 例成年脆弱拟杆菌属菌血症患者进行了回顾性病例对照研究。βL/βLIs 的暴露时间（比值比[OR]，1.25；95%置信区间[CI]，1.08 至 2.31）是唯一的独立耐药风险因素。